1-4 of 4
Richard Soll, PhD
Close
Sort by
Journal Articles

Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Ifat Geron, MS, Annelie Abrahamsson, MS, Charlene Barroga, PhD, Edward Kavelerchik, MD, Jason R. Gotlib, MD MS, John D. Hood, PhD, Jeffrey Durocher, PhD, Chi Ching Mak, PhD, Glen Noronha, PhD, Richard Soll, PhD, Ayalew Tefferi, MD, Kenneth Kaushansky, MD, Catriona H.M. Jamieson, MD PhD
Journal: Blood
Blood (2007) 110 (11): 1526.
https://doi.org/10.1182/blood.V110.11.1526.1526
Published: 2007
Journal Articles

Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.

Terra L. Lasho, MT, Christy Finke, John D. Hood, PhD, Richard Soll, PhD, Glenn Noronha, PhD, Ruben A. Mesa, MD, Catriona Jamieson, MD, PhD, Srdan Verstovsek, MD, PhD, Jorge Cortes, MD, Hagop Kantarjian, MD, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD
Journal: Blood
Blood (2007) 110 (11): 3541.
https://doi.org/10.1182/blood.V110.11.3541.3541
Published: 2007
Journal Articles

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2 V617F or MPL W515K/L Mutations.

Animesh Pardanani, MD, PhD, John Hood, PhD, Terra Lasho, Glenn Noronha, PhD, Christy Finke, Chi Ching Mak, PhD, Ruben Mesa, MD, Hong Zhu, PhD, Richard Soll, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2006) 108 (11): 2680.
https://doi.org/10.1182/blood.V108.11.2680.2680
Published: 2006
Journal Articles

JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.

John Hood, PhD, Jon Cao, PhD, Ehab Hanna, MS, Dan Lohse, PhD, Chi Ching Mak, PhD, Andrew McPherson, PhD, Glenn Noronha, PhD, Joel Renick, MS, Binqi Zheng, PhD, Hong Zhu, PhD, Richard Soll, PhD
Journal: Blood
Blood (2006) 108 (11): 3632.
https://doi.org/10.1182/blood.V108.11.3632.3632
Published: 2006